{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127027","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.699423+00:00","generated_at":"2026-05-30T00:26:30.930664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025","bullets":["Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.","Cash and investments $340.1M, expected to fund operations into H2 2026.","R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.","ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.","Strengthened commercial and medical affairs leadership with three senior appointments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127027","json":"https://secwatch.observer/filing/0000950170-24-127027.json","markdown":"https://secwatch.observer/filing/0000950170-24-127027.md","text":"https://secwatch.observer/filing/0000950170-24-127027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/0000950170-24-127027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/annx-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:26:30.930664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}